Dimensions of valuation in emerging technoscience business
| Valuation | Multiplicity | Collaboration | Branding | Expectations |
|---|---|---|---|---|
| Value Entanglement | Interlacing of social, clinical, health, and commercial value | Exploiting the value potential of an entire ecosystem | Performing competitive advantage in the global market | Promising future competitive advantage and return-on-investment |
| Characterization of Value | Malleability | Attractiveness | Competitiveness | Promissory |
| Embedding of Value | Business model as an instrument for innovative R&D | Biomedical infrastructure and biomedical research with “real-life data” | Efficiency in data sourcing and management | Potential for future revenues |
| Beneficiaries | Scientists, clinicians, healthcare, patients, people, society, economy, entrepreneurs and companies | FinnGen and other researchers, biobanks, clinicians, and pharmaceutical, medical, and IT companies | International academic and business collaborators, Big Pharma, FinnGen, and the domestic business ecosystem | Investors, business collaborators, Big pharma, and domestic business partners |
| Valuation | Multiplicity | Collaboration | Branding | Expectations |
|---|---|---|---|---|
| Value Entanglement | Interlacing of social, clinical, health, and commercial value | Exploiting the value potential of an entire ecosystem | Performing competitive advantage in the global market | Promising future competitive advantage and return-on-investment |
| Characterization of Value | Malleability | Attractiveness | Competitiveness | Promissory |
| Embedding of Value | Business model as an instrument for innovative R&D | Biomedical infrastructure and biomedical research with “real-life data” | Efficiency in data sourcing and management | Potential for future revenues |
| Beneficiaries | Scientists, clinicians, healthcare, patients, people, society, economy, entrepreneurs and companies | FinnGen and other researchers, biobanks, clinicians, and pharmaceutical, medical, and IT companies | International academic and business collaborators, Big Pharma, FinnGen, and the domestic business ecosystem | Investors, business collaborators, Big pharma, and domestic business partners |
Source(s): Table compiled by authors
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.